The aim of our study was to evaluate the effect of enteral nutrition supplemented with arginine in inflammatory markers in surgical head and neck cancer patients. A population of 29 patients with oral and laryngeal cancer were enrolled in a randomized trial. At surgery patients were randomly allocated to two groups: (a) patients receiving an enteral diet supplements with arginine (group I, n ¼ 14); (b) patients receiving an isocaloric, isonitrogenous enteral formula (group II, n ¼ 15). The mean age was 61.1710.8 y (five females/24 males). Characteristics of the patients on enrollment were similar for the two groups. Prealbumin and transferrin improved in both groups. c-reactive protein (CRP) levels decreased in both groups, (group I: 134.5762.5 vs 75.3751 mg/dl:Po0.05) and (group II: 103.6762 vs 43.8734.4 mg/dl:Po0.05). Interleukin-6 (IL-6) improved in both groups (group I: 20.35711.2 vs 6.773.1 pg/ml:Po0.05) and (group II:22.8740 vs 9.9717.7 pg/ml:ns). Tumoral necrosis factor alpha and lymphocytes did not change. In conclusion, both formulas improved IL-6 and CRP levels. Further studies are needed to determine whether type of formula is the key in these patients or genetic background play a main role in inflammatory response.
Surgery and malnutrition have been found to depress the immune system (Van Bokhorst-de van der Schueren et al, 1998) in patients with head and neck cancer. Although immune dysfunction could be multifactorial, this immune system may be modulated by specific nutritional substrates, such as arginine (Daly et al, 1988) . Supplementation with arginine improved wound healing and enhanced immune function in animals by decreasing the T-cell dysfunction associated with injury (Barbul, 1990) . Other studies have shown that arginine increased lymphocytic interleukin-2 production by macrophages . There is evidence suggesting that enteral nutrition, supplemented with different agents including arginine and dietary fiber, improve immune function and reduce postoperative complications, in head and neck cancer patients (Van Bokhorstde van der Schueren et al, 2001) (De Luis et al, 2002) . Our group (De Luis et al, 2003) did not find influence on interleukins blood levels with an arginine-enhanced enteral formula in a randomized clinical trial with two intervention groups. These groups have two differences in enteral formulas (arginine and fiber).
The aim of our study was to evaluate the effect of enteral nutrition supplemented with arginine on c-reactive protein (CRP), interleukin-6 (IL-6) and tumoral necrosis factor alpha (TNFa) in surgical head and neck cancer patients.
A population of 29 patients with a previous weight loss of 5-10% (6 months), (IL-6 levels 45 pg/ml) and oral or laryngeal cancer were enrolled. Exclusion criteria included; severly impaired hepatic function (total bilirubin concentration 43.5 mg/dl) and renal function (serum creatinine concentration 42.5 mg/dl), ongoing infections, steroid treatment and well nourished (weight loss o10% of body weight). The study was a prospective concealed randomized trial carried out from January 2001 to December 2003. Study was blinded. Baseline studies on all patients consisted of complete history taking and physical examination. Informed consent was provided by patients.
At surgery, patients were randomly allocated (sealed envelops) to two groups: (a) patients receiving an enteral diet supplements with arginine (group I, n ¼ 14); (b) patients receiving an isocaloric, isonitrogenous enteral formula without arginine (group II, n ¼ 15) (125 kcal/100 ml, 0.9 g/100 ml dietary fiber, 6.22 g/100 ml proteins). Group I received a daily dose of arginine of 12.5 g during an average of 20 days.
Perioperatively and on postoperative day 6, the following blood parameters were evaluated: prealbumin (mg/dl), transferrin (mg/dl), albumin (g/dl), total number of lymphocytes (10 6 /ml), IL-6 (pg/ml), TNFa (pg/ml) and c-reactive protein (mg/dl).
Fasting blood samples were drawn for measurement of prealbumin (18-28 mg/dl), transferrin (250-350 mg/dl), with an autoanalyzer (Hitachi, ATM, Mannheim, Germany). Lymphocytes (1.2-3.5 Â 10 3 /ml) were analyzed with an analyzer (Beckman Coulter, Inc, LA, CA, USA). Interleukins were measured by immulite analyzer (DPC, Los Angeles, CA, USA). A measure of 100 ml of serum (heparinized plasma) was required to determine IL6 and TNFa, analytical sensitivity of IL-6 and TNFa was 5 and 1.7 pg/ml, respectively. CRP (c-reactive protein) was measured by immunoturbimetry (Roche Diagnostcis GmbH, Mannheim, Germany), analytical sensitivity was 0.5 mg/dl. Samples were assayed in duplicate in 1 day by the same investigator to avoid interinvestigator variability.
Quantitative variables with normal distribution were analyzed with two-tailed paired or unpaired Student's t-test, as needed. Nonparametric variables were analyzed with the Friedman and Wilcoxon tests. To detect a statistical decrease in inflammatory markers (30%), with a power of 85% and an error type I of 5%, 12 patients in each group were necessary. To minimize the potential for introducing bias, all randomized patients were included in the comparisons, irrespective of whether or not and for how long they complied with their allocated regimen (intention-to-treat analysis). A P-value under 0.05 was considered statistically significant.
In all, 29 patients were enrolled in the study. The mean age was 61.1710.8 y (five females/24 males). There were 14 patients in group I (arginine) and 15 patients in the control diet group. Characteristics of the patients and tumor stage (Poissonnet et al., 2000) on enrollment were similar for the two groups, reflecting the homogeneity of the patient (Table 1) .
As shown in Table 2 , no significant intergroup differences in the trend of serum proteins were detected with a significant improvemented in prealbumin and transferrin levels. CRP and IL-6 improved in both groups without changes in TNFa levels and lymphocytes count.
Malnutrition in these patients is due to reduced dietary intake secondary to dysphagia and interleukins secreted by tumor with catabolic action played a dominant role (Todorov et al, 1996) . IL-6 levels correlated with the prognostic and inflammatory nutritional index (Walsh et al, 2003) .
There is evidence suggesting that enteral nutrition, supplemented with immunomodulatory agents including arginine, improve immune function and reduced postoperative complications, in head and neck cancer patients (Riso et al, 2000; Van Bokhorst-de van der Schueren et al, 2001; De Luis et al, 2002) .
It has been suggested that nutrients may improve host immune defences, and specific nutrient substrates seem to act different mechanisms although these formulas combines other immunomodulating nutrients and it is difficult to discern what the treatment effect of arginine alone is (Van Bokhorst-de van der Schueren et al, 1998). Our group (De Luis et al, 2003) showed no differences between two enteral formulas (arginine-and fiber-enhanced formula vs no arginine and no fiber formula) (De Luis et al, 2003) . In this study, perhaps fiber could bias results, due to dietary fiber contained in arginine-enhanced formula and no in control group. Epidemiological studies have shown that subjects in the third and fourth highest quartiles of fiber consumption had a lower risk of elevated CRP (King et al, 2003) . Interleukin-18 concentrations could be modulated from baseline after a high carbohydrate and a high fiber meal (Esposito et al, 2003) . In our new study, with only arginine as different nutrient between both enteral formulas, IL6 and CRP levels decreased in both groups. Perhaps, this decrease in IL-6 levels, previously designed (de Luis et al, 2003) showed only a decrease in CRP, are due to different genetic status of patients (TNFa polymorphisms) (Jacob et al, 1990) or other analytical aspects.
However, other studies in this topic area showed contradictory results. Taylor et al (1999) showed a decrease in CRP levels in head injury patients treated with an enhanced formula without differences in other biochemical parameters. These results were confirmed by Weimann et al (1998) in a group of multiple organ failure patients. Perhaps the differences among studies could be due to different treated patients and different nutrients in enhanced formulas.
In conclusion, both formulas improved IL-6 and RCP levels. Further studies are needed to determine whether type of formula is the key in these patients or genetic background play a main role in inflammatory response.
